From CNBC: 2024-07-26 07:09:52

Bristol Myers Squibb reported better-than-expected second-quarter earnings, with revenue hitting $12.2 billion, a 9% increase from the same period last year. The pharmaceutical giant raised its full-year revenue forecast and adjusted earnings guidance due to strong sales of key drugs like Eliquis and Opdivo.

Despite facing generic competition, sales of Revlimid topped expectations, helping drive revenue for Bristol Myers’ growth portfolio. Income from Opdivo, Reblozyl, Opdualag, and Camzyos also exceeded analyst estimates. Revenue from Abecma, a cell therapy for multiple myeloma, was slightly below expectations but still positive for the company.



Read more at CNBC:: Bristol Myers Squibb (BMY) earnings Q2 2024